Details

Autor(en) / Beteiligte

• de Mendoza, Carmen
• Caballero, Estrella
• Aguilera, Antonio
• Requena, Silvia
• de Lejarazu, Raúl Ortiz
• Pirón, María
• González, Rocío
• Jiménez, Ana
• Roc, Lourdes
• Treviño, Ana
• Benito, Rafael
• Fernández-Alonso, Miriam
• Aguinaga, Aitziber
• Rodríguez, Carmen
• García-Costa, Juan
• Blanco, Lidia
• Ramos, José M
• Calderón, Enrique
• Eirós, José M
• Sauleda, Silvia
• Barreiro, Pablo
• Soriano, Vicente

Titel

HTLV-1 infection and disease in Spain

Ist Teil von

• AIDS (London), 2017-05

Ort / Verlag

England

Erscheinungsjahr

2017

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• : Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite roughly 15 million people are chronically infected worldwide. Lifelong less than 10% of carriers develop life-threatening diseases, mostly a subacute myelopathy known as tropical spastic paraparesis (TSP) and a lymphoproliferative disorder named adult T-cell leukemia (ATL). HTLV-1 is efficiently transmitted perinatally (breastfeeding), sexually (more from male to female) and parenterally (transfusions, injection drug use and transplants). To date there is neither prophylactic vaccine nor effective antiviral therapy.A total of 327 cases of HTLV-1 infection had been reported at the HTLV-1 Spanish registry until December 2016, of whom 34 had been diagnosed with TSP and 25 with ATL. Overall 62% were Latin American immigrants and 13% were persons of African origin. The incidence of HTLV-1 in Spain has remained stable for nearly a decade with 20-25 new cases yearly. Of the 21 newly diagnosed HTLV-1 cases during year 2016, one was a native Spaniard pregnant woman, and four presented with symptomatic disease, including three with ATL and one with TSP.Underdiagnosis of HTLV-1 in Spain must be high (iceberg model), which may account for the disproportionate high rate of symptomatic cases (almost 20%) and the late recognition of preventable HTLV-1 transmissions in special populations, such as newborns and transplant recipients. Our current estimate is of 10,000 persons living with HTLV-1 infection in Spain. Given the large flux of immigrants and visitors from HTLV-1 endemic regions to Spain, the expansion of HTLV-1 screening policies is warranted. At this time, it seems worth recommending HTLV testing to all donor/recipient organ transplants and pregnant women regardless place of birth. Although current leukoreduction procedures largely prevent HTLV-1 transmission by blood transfusions, HTLV testing of all first-time donors should be cost-effective contributing to unveil asymptomatic unaware HTLV-1 carriers.